Total Payments
$3,282
2024 Payments
$922.79
Companies
24
Transactions
198
Medicare Patients
1,376
Medicare Billing
$120,593
Payment Breakdown by Category
Food & Beverage$3,248 (99.0%)
Education$33.84 (1.0%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,248 | 196 | 99.0% |
| Education | $33.84 | 2 | 1.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $956.41 | 59 | $0 (2024) |
| Lilly USA, LLC | $606.91 | 50 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $419.25 | 15 | $0 (2024) |
| Amgen Inc. | $409.14 | 24 | $0 (2024) |
| ABBVIE INC. | $145.98 | 8 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $85.26 | 4 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $82.96 | 4 | $0 (2023) |
| Abbott Laboratories | $68.39 | 3 | $0 (2024) |
| Dexcom, Inc. | $59.93 | 4 | $0 (2024) |
| Exact Sciences Corporation | $49.60 | 3 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $922.79 | 51 | Novo Nordisk Inc ($241.81) |
| 2023 | $1,135 | 71 | Lilly USA, LLC ($357.84) |
| 2022 | $587.14 | 31 | Novo Nordisk Inc ($206.51) |
| 2021 | $576.81 | 41 | Novo Nordisk Inc ($219.87) |
| 2020 | $60.27 | 4 | Novo Nordisk Inc ($31.82) |
All Payment Transactions
198 individual payment records from CMS Open Payments — Page 3 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/05/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $3.35 | General |
| Category: Diabetes | ||||||
| 12/28/2023 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $7.27 | General |
| Category: Diabetes | ||||||
| 12/22/2023 | Alvogen Inc | TERIPARATIDE (Drug) | Food and Beverage | In-kind items and services | $18.47 | General |
| Category: OSTEOPOROSIS | ||||||
| 12/18/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $17.81 | General |
| Category: Gastroenterology | ||||||
| 12/18/2023 | Optinose US, Inc. | Xhance (Drug) | Food and Beverage | In-kind items and services | $17.28 | General |
| Category: Otolaryngology (Ear, Nose, Throat) | ||||||
| 12/12/2023 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $12.93 | General |
| Category: Inflammation | ||||||
| 12/08/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $20.66 | General |
| Category: NEUROSCIENCE | ||||||
| 12/01/2023 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $13.89 | General |
| Category: Diabetes | ||||||
| 11/11/2023 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $17.79 | General |
| Category: Diabetes | ||||||
| 11/08/2023 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $6.85 | General |
| Category: Diabetes | ||||||
| 11/08/2023 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $0.48 | General |
| Category: Diabetes | ||||||
| 11/03/2023 | AbbVie Inc. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $13.57 | General |
| Category: NEUROSCIENCE | ||||||
| 11/02/2023 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $19.05 | General |
| Category: Inflammation | ||||||
| 10/31/2023 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $10.15 | General |
| Category: Diabetes | ||||||
| 10/30/2023 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $21.39 | General |
| Category: Diabetes | ||||||
| 10/21/2023 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $17.58 | General |
| Category: Cardio-renal | ||||||
| 10/13/2023 | AbbVie Inc. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $15.64 | General |
| Category: NEUROSCIENCE | ||||||
| 10/12/2023 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $12.02 | General |
| Category: Inflammation | ||||||
| 10/11/2023 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $22.67 | General |
| Category: Diabetes | ||||||
| 09/28/2023 | Amgen Inc. | Prolia (Biological) | Food and Beverage | In-kind items and services | $97.43 | General |
| Category: Bone Health | ||||||
| 09/28/2023 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $10.69 | General |
| Category: Diabetes | ||||||
| 09/25/2023 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $19.08 | General |
| Category: Diabetes | ||||||
| 09/18/2023 | Optinose US, Inc. | Xhance (Drug) | Food and Beverage | In-kind items and services | $15.04 | General |
| Category: Otolaryngology (Ear, Nose, Throat) | ||||||
| 09/18/2023 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $8.62 | General |
| Category: Diabetes | ||||||
| 09/15/2023 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $18.34 | General |
| Category: Diabetes | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 194 | 365 | $63,699 | $21,307 |
| 2022 | 10 | 390 | 542 | $49,955 | $33,355 |
| 2021 | 10 | 331 | 504 | $47,600 | $32,832 |
| 2020 | 9 | 461 | 583 | $78,458 | $33,098 |
Total Patients
1,376
Total Services
1,994
Medicare Billing
$120,593
Procedure Codes
36
All Medicare Procedures & Services
36 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 80 | 173 | $44,074 | $15,341 | 34.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 43 | 66 | $11,993 | $4,177 | 34.8% |
| 99497 | Advance care planning, first 30 minutes | Office | 2023 | 18 | 18 | $3,032 | $1,251 | 41.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 17 | 25 | $774.00 | $258.48 | 33.4% |
| G0442 | Annual alcohol misuse screening, 5 to 15 minutes | Office | 2023 | 13 | 13 | $490.00 | $228.67 | 46.7% |
| 81003 | Automated urinalysis test | Office | 2023 | 11 | 14 | $666.00 | $30.80 | 4.6% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2023 | 12 | 56 | $2,670 | $20.75 | 0.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 97 | 203 | $26,390 | $18,737 | 71.0% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 46 | 46 | $9,200 | $5,789 | 62.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 52 | 70 | $6,650 | $4,254 | 64.0% |
| 99497 | Advance care planning, first 30 minutes | Office | 2022 | 31 | 31 | $3,100 | $2,520 | 81.3% |
| G0442 | Annual alcohol misuse screening, 15 minutes | Office | 2022 | 50 | 50 | $1,250 | $899.86 | 72.0% |
| G0444 | Annual depression screening, 15 minutes | Office | 2022 | 27 | 27 | $675.00 | $477.36 | 70.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 16 | 26 | $780.00 | $288.08 | 36.9% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 18 | 19 | $1,045 | $207.42 | 19.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 29 | 37 | $370.00 | $109.71 | 29.7% |
| 81003 | Automated urinalysis test | Office | 2022 | 24 | 33 | $495.00 | $73.12 | 14.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 96 | 227 | $29,510 | $21,588 | 73.2% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 36 | 36 | $7,200 | $4,710 | 65.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 40 | 51 | $4,845 | $3,137 | 64.8% |
| 99497 | Advance care planning by the physician or other qualified health care professional, first 30 minutes | Office | 2021 | 20 | 20 | $2,000 | $1,685 | 84.3% |
| G0442 | Annual alcohol misuse screening, 15 minutes | Office | 2021 | 37 | 37 | $925.00 | $681.17 | 73.6% |
| G0444 | Annual depression screening, 15 minutes | Office | 2021 | 18 | 18 | $450.00 | $331.38 | 73.6% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 19 | 27 | $810.00 | $302.40 | 37.3% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2021 | 18 | 19 | $1,045 | $208.26 | 19.9% |
About Dr. Larissa Riojas, DO
Dr. Larissa Riojas, DO is a Family Medicine healthcare provider based in Weslaco, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/04/2014. The National Provider Identifier (NPI) number assigned to this provider is 1104239425.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Larissa Riojas, DO has received a total of $3,282 in payments from pharmaceutical and medical device companies, with $922.79 received in 2024. These payments were reported across 198 transactions from 24 companies. The most common payment nature is "Food and Beverage" ($3,248).
As a Medicare-enrolled provider, Riojas has provided services to 1,376 Medicare beneficiaries, totaling 1,994 services with total Medicare billing of $120,593. Data is available for 4 years (2020–2023), covering 36 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location Weslaco, TX
- Active Since 06/04/2014
- Last Updated 10/12/2020
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1104239425
Products in Payments
- Ozempic (Drug) $582.13
- Kerendia (Drug) $419.25
- MOUNJARO (Drug) $364.00
- Rybelsus (Drug) $274.05
- JARDIANCE (Drug) $182.68
- Otezla (Drug) $123.19
- Prolia (Biological) $97.43
- EVENITY (Biological) $93.39
- Aimovig (Biological) $74.39
- TRULICITY (Drug) $72.97
- FREESTYLE LIBRE 3 (Device) $68.39
- XARELTO (Drug) $67.10
- RYBELSUS (Drug) $52.61
- Cologuard Collection Kit (Device) $49.60
- EMGALITY (Drug) $49.32
- UBRELVY (Drug) $43.43
- Talicia (Drug) $43.01
- QULIPTA (Drug) $42.68
- VRAYLAR (Drug) $36.25
- NURTEC ODT (Drug) $36.12
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Weslaco
Melecia Fuentes, M.d, M.D
Family Medicine — Payments: $7,400
Family Medicine $7,400
Dr. Alejandro Fuentes, M.d, M.D
Family Medicine — Payments: $5,116
Family Medicine $5,116
Dr. Donna Mery, M.d, M.D
Family Medicine — Payments: $4,323
Family Medicine $4,323
Dr. Roger Heredia, M.d, M.D
Family Medicine — Payments: $3,405
Family Medicine $3,405
Martha Cano, Md, MD
Family Medicine — Payments: $2,563
Family Medicine $2,563
Pamela Ramirez Stroman, M.d, M.D
Family Medicine — Payments: $2,176
Family Medicine $2,176